お問い合わせ

Antihyperlipidemic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Statins, Cholesterol Absorption Inhibitors), By Indication, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

出版社

Grand View Research
グランドビューリサーチ

出版年月

2026年9月8日

電子版価格

US$5,950
シングルユーザライセンス（印刷不可）
ライセンス・価格情報／注文方法はこちら

納期

電子ファイル - ご注文後3営業日前後

ページ数

150

言語

英語

英語原文をAIを使って翻訳しています。

図表リスト

お問い合わせ

お問合せ種類／内容 *	見積り依頼購入希望サンプル依頼納期についてライセンスについて内容についてその他（下記にご記入ください）補足が有ればご記入ください
貴社名*
ご担当者名 *	姓名
メールアドレス *

ページTOPに戻る

図表リスト

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Antihyperlipidemic Drugs Market, By Region, 2021 - 2033 (USD Billion)
Table 4 Global Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 5 Global Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 6 Global Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 7 Global Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 8 North America Antihyperlipidemic Drugs Market, By Country, 2021 - 2033 (USD Billion)
Table 9 North America Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 10 North America Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 11 North America Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 12 North America Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 13 U.S. Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 14 U.S. Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 15 U.S. Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 16 U.S. Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 17 Canada Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 18 Canada Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 19 Canada Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 20 Canada Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 21 Mexico Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 22 Mexico Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 23 Mexico Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 24 Mexico Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 25 Europe Antihyperlipidemic Drugs Market, By Country, 2021 - 2033 (USD Billion)
Table 26 Europe Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 27 Europe Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 28 Europe Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 29 Europe Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 30 UK Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 31 UK Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 32 UK Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 33 UK Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 34 Germany Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 35 Germany Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 36 Germany Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 37 Germany Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 38 France Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 39 France Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 40 France Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 41 France Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 42 Italy Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 43 Italy Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 44 Italy Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 45 Italy Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 46 Spain Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 47 Spain Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 48 Spain Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 49 Spain Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 50 Norway Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 51 Norway Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 52 Norway Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 53 Norway Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 54 Denmark Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 55 Denmark Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 56 Denmark Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 57 Denmark Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 58 Sweden Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 59 Sweden Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 60 Sweden Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 61 Sweden Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 62 Asia Pacific Antihyperlipidemic Drugs Market, By Country, 2021 - 2033 (USD Billion)
Table 63 Asia Pacific Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 64 Asia Pacific Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 65 Asia Pacific Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 66 Asia Pacific Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 67 Japan Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 68 Japan Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 69 Japan Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 70 Japan Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 71 China Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 72 China Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 73 China Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 74 China Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 75 India Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 76 India Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 77 India Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 78 India Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 79 Australia Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 80 Australia Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 81 Australia Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 82 Australia Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 83 South Korea Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 84 South Korea Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 85 South Korea Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 86 South Korea Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 87 Thailand Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 88 Thailand Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 89 Thailand Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 90 Thailand Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 91 Latin America Antihyperlipidemic Drugs Market, By Country, 2021 - 2033 (USD Billion)
Table 92 Latin America Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 93 Latin America Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 94 Latin America Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 95 Latin America Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 96 Brazil Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 97 Brazil Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 98 Brazil Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 99 Brazil Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 100 Argentina Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 101 Argentina Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 102 Argentina Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 103 Argentina Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 104 Middle East & Africa Antihyperlipidemic Drugs Market, By Country, 2021 - 2033 (USD Billion)
Table 105 Middle East & Africa Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 106 Middle East & Africa Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 107 Middle East & Africa Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 108 Middle East & Africa Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 109 South Africa Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 110 South Africa Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 111 South Africa Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 112 South Africa Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 113 Saudi Arabia Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 114 Saudi Arabia Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 115 Saudi Arabia Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 116 Saudi Arabia Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 117 UAE Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 118 UAE Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 119 UAE Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 120 UAE Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)
Table 121 Kuwait Antihyperlipidemic Drugs Market, By Drug Class, 2021 - 2033 (USD Billion)
Table 122 Kuwait Antihyperlipidemic Drugs Market, By Indication, 2021 - 2033 (USD Billion)
Table 123 Kuwait Antihyperlipidemic Drugs Market, By Route of Administration, 2021 - 2033 (USD Billion)
Table 124 Kuwait Antihyperlipidemic Drugs Market, By Distribution Channel, 2021 - 2033 (USD Billion)

List of Figures

Fig. 1 Antihyperlipidemic Drugs Market Segmentation
Fig. 2 Market Research Process
Fig. 3 Data Triangulation Techniques
Fig. 4 Primary Research Pattern
Fig. 5 Market Research Approaches
Fig. 6 Value-Chain-Based Sizing & Forecasting
Fig. 7 Market Formulation & Validation
Fig. 8 Market Snapshot
Fig. 9 Competitive Landscape
Fig. 10 Antihyperlipidemic Drugs Market Dynamics
Fig. 11 Antihyperlipidemic Drugs Market: Porter’s Five Forces Analysis
Fig. 12 Antihyperlipidemic Drugs Market: PESTLE Analysis
Fig. 13 Drug Class Market, 2021 - 2033 (USD Billion)
Fig. 14 Statins Market, 2021 - 2033 (USD Billion)
Fig. 15 Cholesterol Absorption Inhibitors Market, 2021 - 2033 (USD Billion)
Fig. 16 PCSK9 Inhibitors Market, 2021 - 2033 (USD Billion)
Fig. 17 ATP-Citrate Lyase (ACL) Inhibitors Market, 2021 - 2033 (USD Billion)
Fig. 18 Fibrates Market, 2021 - 2033 (USD Billion)
Fig. 19 Bile Acid Sequestrants Market, 2021 - 2033 (USD Billion)
Fig. 20 Omega-3 Fatty Acid Products Market, 2021 - 2033 (USD Billion)
Fig. 21 Niacin Market, 2021 - 2033 (USD Billion)
Fig. 22 Combination Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 23 Others Market, 2021 - 2033 (USD Billion)
Fig. 24 Indication Market, 2021 - 2033 (USD Billion)
Fig. 25 Hypercholesterolemia Market, 2021 - 2033 (USD Billion)
Fig. 26 Hypertriglyceridemia Market, 2021 - 2033 (USD Billion)
Fig. 27 Mixed Dyslipidemia Market, 2021 - 2033 (USD Billion)
Fig. 28 Others Market, 2021 - 2033 (USD Billion)
Fig. 29 Route of Administration Market, 2021 - 2033 (USD Billion)
Fig. 30 Oral Market, 2021 - 2033 (USD Billion)
Fig. 31 Subcutaneous Market, 2021 - 2033 (USD Billion)
Fig. 32 Others Market, 2021 - 2033 (USD Billion)
Fig. 33 Distribution Channel Market, 2021 - 2033 (USD Billion)
Fig. 34 Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
Fig. 35 Specialty Pharmacies Market, 2021 - 2033 (USD Billion)
Fig. 36 Retail Pharmacies Market, 2021 - 2033 (USD Billion)
Fig. 37 Mail-Order / Online Pharmacies Market, 2021 - 2033 (USD Billion)
Fig. 38 Others Market, 2021 - 2033 (USD Billion)
Fig. 39 Antihyperlipidemic Drugs Market Revenue, By Region
Fig. 40 Regional Marketplace: Key Takeaways
Fig. 41 North America Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 42 U.S. Country Dynamics
Fig. 43 U.S. Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 44 Canada Country Dynamics
Fig. 45 Canada Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 46 Mexico Country Dynamics
Fig. 47 Mexico Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 48 Europe Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 49 UK Country Dynamics
Fig. 50 UK Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 51 Germany Country Dynamics
Fig. 52 Germany Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 53 France Country Dynamics
Fig. 54 France Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 55 Italy Country Dynamics
Fig. 56 Italy Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 57 Spain Country Dynamics
Fig. 58 Spain Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 59 Norway Country Dynamics
Fig. 60 Norway Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 61 Sweden Country Dynamics
Fig. 62 Sweden Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 63 Denmark Country Dynamics
Fig. 64 Denmark Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 65 Asia Pacific Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 66 Japan Country Dynamics
Fig. 67 Japan Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 68 China Country Dynamics
Fig. 69 China Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 70 India Country Dynamics
Fig. 71 India Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 72 Australia Country Dynamics
Fig. 73 Australia Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 74 South Korea Country Dynamics
Fig. 75 South Korea Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 76 Thailand Country Dynamics
Fig. 77 Thailand Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 78 Latin America Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 79 Brazil Country Dynamics
Fig. 80 Brazil Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 81 Argentina Country Dynamics
Fig. 82 Argentina Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 83 MEA Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 84 South Africa Country Dynamics
Fig. 85 South Africa Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 86 Saudi Arabia Country Dynamics
Fig. 87 Saudi Arabia Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 88 UAE Country Dynamics
Fig. 89 UAE Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 90 Kuwait Country Dynamics
Fig. 91 Kuwait Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
Fig. 92 Company Categorization
Fig. 93 Company Market Position Analysis
Fig. 94 Strategic Framework

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Antihyperlipidemic Drugs Market Summary

The global antihyperlipidemic drugs market size was valued at USD 14.3 billion in 2025 and is projected to grow from USD 15.0 billion in 2026 to USD 22.0 billion by 2033, at a CAGR of 5.6% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.2% in 2025. The market is supported by the ongoing need to manage elevated LDL cholesterol and triglyceride levels and to reduce the risk of cardiovascular disease.

Statins remain the main treatment option because of their established use, availability of generic products, and role in long-term cholesterol management. However, treatment is expanding beyond statins as patients with cardiovascular risk may require additional LDL-lowering therapies such as ezetimibe, bempedoic acid, PCSK9 inhibitors, and inclisiran. The market also includes therapies for high triglyceride levels, including fibrates and prescription omega-3 products. Growing focus on lipid testing, earlier treatment, and management of patients who do not achieve adequate lipid control with statins is supporting demand for combination and non-statin therapies. Treatment decisions are increasingly based on overall cardiovascular risk, LDL-C levels, and patient-specific factors, supporting continued use of both established and newer antihyperlipidemic drugs.

Global Antihyperlipidemic Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antihyperlipidemic drugs market report based on drug class, indication, route of administration, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
• Statins
• Cholesterol Absorption Inhibitors
• PCSK9 Inhibitors
• ATP-Citrate Lyase (ACL) Inhibitors
• Fibrates
• Bile Acid Sequestrants
• Omega-3 Fatty Acid Products
• Niacin
• Combination Antihyperlipidemic Drugs
• Others
• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
• Hypercholesterolemia
• Hypertriglyceridemia
• Mixed Dyslipidemia
• Others
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Oral
• Subcutaneous
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Mail-Order / Online Pharmacies
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Indication
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Antihyperlipidemic Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis

Chapter 4. Antihyperlipidemic Drugs Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2025 & 2033
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
4.4. Statins
4.4.1. Statins Market, 2021 - 2033 (USD Billion)
4.5. Cholesterol Absorption Inhibitors
4.5.1. Cholesterol Absorption Inhibitors Market, 2021 - 2033 (USD Billion)
4.6. PCSK9 Inhibitors
4.6.1. PCSK9 Inhibitors Market, 2021 - 2033 (USD Billion)
4.7. ATP-Citrate Lyase (ACL) Inhibitors
4.7.1. ATP-Citrate Lyase (ACL) Inhibitors Market, 2021 - 2033 (USD Billion)
4.8. Fibrates
4.8.1. Fibrates Market, 2021 - 2033 (USD Billion)
4.9. Bile Acid Sequestrants
4.9.1. Bile Acid Sequestrants Market, 2021 - 2033 (USD Billion)
4.10. Omega-3 Fatty Acid Products
4.10.1. Omega-3 Fatty Acid Products Market, 2021 - 2033 (USD Billion)
4.11. Niacin
4.11.1. Niacin Market, 2021 - 2033 (USD Billion)
4.12. Combination Antihyperlipidemic Drugs
4.12.1. Combination Antihyperlipidemic Drugs Market, 2021 - 2033 (USD Billion)
4.13. Others
4.13.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. Antihyperlipidemic Drugs Market: Indication Business Analysis
5.1. Indication Market Share, 2025 & 2033
5.2. Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
5.4. Hypercholesterolemia
5.4.1. Hypercholesterolemia Market, 2021 - 2033 (USD Billion)
5.5. Hypertriglyceridemia
5.5.1. Hypertriglyceridemia Market, 2021 - 2033 (USD Billion)
5.6. Mixed Dyslipidemia
5.6.1. Mixed Dyslipidemia Market, 2021 - 2033 (USD Billion)
5.7. Others
5.7.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Antihyperlipidemic Drugs Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2025 & 2033
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
6.4. Oral
6.4.1. Oral Market, 2021 - 2033 (USD Billion)
6.5. Subcutaneous
6.5.1. Subcutaneous Market, 2021 - 2033 (USD Billion)
6.6. Others
6.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Antihyperlipidemic Drugs Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2025 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
7.5. Specialty Pharmacies
7.5.1. Specialty Pharmacies Market, 2021 - 2033 (USD Billion)
7.6. Retail Pharmacies
7.6.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
7.7. Mail-Order / Online Pharmacies
7.7.1. Mail-Order / Online Pharmacies Market, 2021 - 2033 (USD Billion)
7.8. Others
7.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 8. Antihyperlipidemic Drugs Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2025 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America Antihyperlipidemic Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. U.S. Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. Canada Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. Mexico Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5. Europe
8.5.1. Europe Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. UK Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. Germany Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement Framework
8.5.4.5. France Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Regulatory Framework
8.5.5.4. Reimbursement Framework
8.5.5.5. Italy Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Target Disease Prevalence
8.5.6.3. Regulatory Framework
8.5.6.4. Reimbursement Framework
8.5.6.5. Spain Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. Target Disease Prevalence
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement Framework
8.5.7.5. Denmark Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. Target Disease Prevalence
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement Framework
8.5.8.5. Sweden Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Target Disease Prevalence
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement Framework
8.5.9.5. Norway Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.6. Asia Pacific
8.6.1. Asia Pacific Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. Japan Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. China Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. India Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Australia Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement Framework
8.6.6.5. South Korea Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Target Disease Prevalence
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement Framework
8.6.7.5. Thailand Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.7. Latin America
8.7.1. Latin America Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Target Disease Prevalence
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement Framework
8.7.2.5. Brazil Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Target Disease Prevalence
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement Framework
8.7.3.5. Argentina Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Target Disease Prevalence
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement Framework
8.8.2.5. South Africa Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Target Disease Prevalence
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement Framework
8.8.3.5. Saudi Arabia Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Target Disease Prevalence
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement Framework
8.8.4.5. UAE Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Target Disease Prevalence
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement Framework
8.8.5.5. Kuwait Antihyperlipidemic Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Amgen
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Merck & Co.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Sanofi
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Regeneron
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Novartis
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. AstraZeneca
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Esperion Therapeutics
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Viatris
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives

ページTOPに戻る

List of Tables/Graphs

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

Grand View Research社の医薬品分野での最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

Grand View Research社はどのような調査会社ですか?

グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

ページTOPに戻る

A	ABIリサーチ
	ACGリサーチ
	アディティブマニファクチャリング
	アナリシスメイソン
	アライドマーケットリサーチ
	アーゾスアナリティクス
	エーピーオーリサーチ
B	BCCリサーチ
	バーンズレポート
	ビズウィットリサーチ&コンサルティング
	ベルグインサイト社
	ボッソンリサーチ
	ボナファイドリサーチ
C	CIR社
	カレンインターナショナル
	ケムアナリスト
	コンストラック360
D	DIResearch
	ディリジェンスインサイト
	デイダラスコンサルティング
	デダルリサーチ
	デローログループ
	データMインテリジェンス
	データセンタプライシング (Tariff Consultancy)
	データブリッジマーケットリサーチ
E	EIUクリアステート
	ENF社
	イースタンマネージメントグループ社
F	Fatpos グローバル
	フェアフィールドマーケットリサーチ
	フューチャーマーケッツインク
	フューチャーマーケットインサイツ
G	ガイドハウス
	グッドインテリジェンス
	グランドビューリサーチ
	グローバルデータ
H	HNYリサーチ
I	IHLグループ
	アイエイチアールインサイト
	アイディーテックエックス
	アイトニクス
	アイマークサービス
	イダテ社
	インクウッドリサーチ
J	ジュニパーリサーチ社
L	LPインフォメーション
	ルシンテル
	ロジスティクス IQ
M	マイクロテックコンサルタンツ社
	マーケッツアンドマーケッツ
	マーケットフォーキャスト
	マーケットライン
	マーケットリサーチフューチャー (MRFR)
	モードーインテリジェンス
O	オンワールドリサーチ
	オージーアナリシス
P	パークスアソシエイツ社
	パーシスタンスマーケットリサーチ
	ペイネクスト360
	ポリシートラッカー
	ポーマノックパブリケーションズ社
Q	QYリサーチ
	クアインテルリサーチ
R	Renubリサーチ
	リサーチネスター
	リシンクテクノロジーリサーチ
	リテールバンキングリサーチ
	リードエレクトロニクスリサーチ社
	ルーツアナリシス
S	SBDジャパン
	SNSテレコム&IT
	シグナルズリサーチグループ社
	スウォットレポート
	北京真友堂国際技術発展有限公司
T	インフォメーションネットワーク
	ザ・インサイトパートナーズ
	ザ・ビジネスリサーチカンパニー
	テクナビオ
	テックサイリサーチ
	テレコムズプライシング (Tariff Consultancy)
	テレジオグラフィー
	トランスペアレンシーマーケットリサーチ
	トレンドフォース
U	ユニブデイトズマーケットインサイト
V	VDCリサーチグループ社
	ヴィジョンゲイン社
W	ウェブフィートリサーチ社
X	ゼイラムアナリティクス
日	インプレス総合研究所
	エヌ・ティー・エス
	シード・プランニング
	ネオテクノロジー
	パテントテック社
	ミライロリサーチ
	未来トレンド研究機構 (旧：ESP総研）
	次世代社会システム研究開発機構
	興人社
	AQU先端テクノロジー総研
	アクアビット
	シーエムシー・リサーチ
	データリソース
	データライン・リサーチ・ネットワーク株式会社
	アイ・ティ・アール
	エムシーエイ
	日経BP社
	ROA
	産業タイムズ社
	ユーディーアール

詳細検索

詳細検索

Antihyperlipidemic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Statins, Cholesterol Absorption Inhibitors), By Indication, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

お問い合わせ

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

Grand View Research社の医薬品分野での最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

Grand View Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?

詳細検索

詳細検索

Antihyperlipidemic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Statins, Cholesterol Absorption Inhibitors), By Indication, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

お問い合わせ

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

Grand View Research社の 医薬品分野 での最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

Grand View Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?

Grand View Research社の医薬品分野での最新刊レポート